Correction to the Article “Recommendations for Reducing the Environmental Impact of Inhalers in Portugal: Consensus Document”, Published on Acta Med Port 2024 Sep;37(9):654-661

Authors

  • Luí­s Campos Hospital CUF Tejo. Lisboa; Conselho Português para a Saúde e Ambiente. Lisboa.
  • Paula Rosa Serviço de Pneumologia. Hospital de Vila Franca de Xira Unidade Local de Saúde Estuário do Tejo. Vila Franca de Xira; Hospital CUF Descobertas. Lisboa; Sociedade Portuguesa de Pneumologia. Lisboa.
  • Pedro Carreiro Martins Serviço de Imunoalergologia. Hospital Dona Estefânia. Unidade Local de Saúde São José. Lisboa; NOVA Medical School. Universidade NOVA de Lisboa. Lisboa; Sociedade Portuguesa de Alergologia e Imunologia Clínica. Lisboa.
  • Bilhota Xavier Sociedade Portuguesa de Pediatria. Lisboa; Secção Pediátrica da Qualidade e Segurança. Sociedade Portuguesa de Pediatria. Lisboa.
  • Pedro Leuschner Serviço de Medicina Interna. Centro Hospitalar Universitário de Santo António. Porto; Instituto de Ciência Biomédicas Abel Salazar. Porto; Sociedade Portuguesa de Medicina Interna. Lisboa.
  • Maria Inês M. Marques Unidade de Saúde Familiar Reynaldo dos Santos. Unidade Local de Saúde Estuário do Tejo. Vila Franca de Xira; Associação Portuguesa de Medicina Geral e Familiar. Lisboa.
  • José Albino Associação Respira. Lisboa.
  • Carlos Robalo Cordeiro Sociedade Portuguesa de Pneumologia. Lisboa; Serviço de Pneumologia. Centro Hospitalar Universitário de Coimbra. Unidade Local de Saúde de Coimbra. Coimbra; Faculdade de Medicina. Universidade de Coimbra. Coimbra. 

DOI:

https://doi.org/10.20344/amp.22395

Keywords:

Administration, Inhalation, Carbon Footprint, Dry Powder Inhalers, Greenhouse Gases, Metered Dose Inhalers, Nebulizers and Vaporizers, Portugal

Abstract

N/A.

Downloads

Download data is not yet available.

References

United Nations. The human right to a clean, healthy and sustainable environment: draft resolution. 2022. [consultado 2024 mai 16]. Disponível em: https://digitallibrary.un.org/record/3982508?ln=en&v=pdf.

World Health Organization. Climate change and health. [consultado 2024 mai 16]. Disponível em: https://www.who.int/news-room/factsheets/ detail/climate-change-and-health.

Ribeiro HR. Poluição, um veneno silencioso para a saúde humana. Rev Ciência Elem. 2019;7:1-5. DOI: https://doi.org/10.24927/rce2019.069

United States Environmental Protection Agency. Climate impacts on human health. [consultado 2024 mai 18]. Disponível em: https://19january2017snapshot.epa.gov/climate-impacts/climateimpacts- human-health_.html.

Health Care Without Harm. Health care’s climate footprint. 2019. [consultado 2024 mai 16]. Disponível em: https:// noharm-global.org/sites/default/files/documents-files/5961/ HealthCaresClimateFootprint_092319.pdf.

Wilkinson AJ, Braggins R, Steinbach I, Smith J. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9:e028763. DOI: https://doi.org/10.1136/bmjopen-2018-028763

Jornal Oficial da União Europeia. Regulamento (UE) 2024/573 do Parlamento Europeu e do Conselho, de 7 de fevereiro de 2024, relativo aos gases fluorados com efeito de estufa, que altera a Diretiva (UE) 2019/1937 e que revoga o Regulamento (UE) n.º 517/2014. 2024. [consultado 2024 mai 19]. Disponível em: https://eur-lex.europa.eu/ legal-content/PT/TXT/PDF/?uri=OJ:L_202400573.

Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur Respir J. 2020;55:2000048. DOI: https://doi.org/10.1183/13993003.00048-2020

Khan N, Walpole SC, Rostkowska OM, Smith JN, Miller FA. Do clinical practice guidelines follow sustainable healthcare principles? A review of respiratory guidance. PLOS Sustain Transform. 2023;2:e0000078. DOI: https://doi.org/10.1371/journal.pstr.0000078

Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med. 2023;33:24. DOI: https://doi.org/10.1038/s41533-023-00346-7

Woodcock A, Beeh KM, Sagara H, Aumônier S, Addo-Yobo E, Khan J, et al. The environmental impact of inhaled therapy: making informed treatment choices. Eur Respir J. 2022;60:2102106. DOI: https://doi.org/10.1183/13993003.02106-2021

Wilkinson A, Woodcock A. The environmental impact of inhalers for asthma: a green challenge and a golden opportunity. Br J Clin Pharmacol. 2022;88:3016-22. DOI: https://doi.org/10.1111/bcp.15135

Alzaabi A, Bell JP, Montero-Arias F, Preço DB, Jackson DJ, Hao-Chien W, et al. Greenhouse gas emissions from respiratory treatments: results from the SABA CARBON International Study. Adv Ther. 2023;40:4836- 56. DOI: https://doi.org/10.1007/s12325-023-02663-2

Jeswani HK, Azapagic A. Life cycle environmental impacts of inhalers. J Clean Prod. 2019;237:117733. DOI: https://doi.org/10.1016/j.jclepro.2019.117733

Novartis. Case study: Breezhaler® Carbon Footprint. [consultado 2024 mai 21]. Disponível em: https://www.novartis.com/esg/environmentalsustainability/ climate/case-study-breezhaler-carbon-footprint.

Panigone S, Sandri F, Ferri R, Volpato A, Nudo E, Nicolini G. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res. 2020;7:e000571. DOI: https://doi.org/10.1136/bmjresp-2020-000571

Borenius K, Vartiainen V, Takala A, Haikarainen J, Parker G, Paronen N, et al. Life cycle assessment (LCA) and cradle-to-grave (CTG) carbon footprint of a multidose reservoir dry powder inhaler. Sheffield: European Respiratory Society; 2020. DOI: https://doi.org/10.1183/13993003.congress-2020.3183

Hänsel M, Bambach T, Wachtel H. Reduced environmental impact of the Reusable Respimat® Soft MistTM inhaler compared with pressurised metered-dose inhalers. Adv Ther. 2019;36:2487-92. DOI: https://doi.org/10.1007/s12325-019-01028-y

Janson C, Henderson R, Löfdahl M, Hedberg M, Sharma R, Wilkinson AJK, et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020:75:82-4. DOI: https://doi.org/10.1136/thoraxjnl-2019-213744

National Institute for Health and Care Excellence. Asthma inhalers and climate change. [consultado 2024 mai 20]. Disponível em: https:// www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthma-patientdecision- aid-pdf-6727144573.

Smith J, Bansal A, Barron-Snowdon J, Keeley D, Wilkinson A. How to reduce the carbon footprint of inhaler prescribing. [consultado 2024 mai 20]. Disponível em: https://s40639.pcdn.co/wp-content/uploads/ Reducing-Carbon-Footprint-of-Inhaler-Prescribing-v3.3.2.pdf.

PrescQIPP. Bulletin 295: inhaler carbon footprint. [consultado 2024 mai 20]. Disponível em: https://www.prescqipp.info/our-resources/bulletins/ bulletin-295-inhaler-carbon-footprint/.

NHS Business Services Authority. Respiratory - carbon impact dashboard [consultado 2024 mai 28]. Disponível em: https://www. nhsbsa.nhs.uk/access-our-data-products/epact2/dashboards-andspecifications/ respiratory-carbon-impact-dashboard.

Fulford B, Mezzi K, Aumônier S, Finkbeiner M. Carbon footprints and life cycle assessments of inhalers: a review of published evidence. Sustainability. 2022;14:7106. DOI: https://doi.org/10.3390/su14127106

Woodcock A, Janson C, Rees J, Frith L, Löfdahl M, Moore A, et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022;77:1187-92. DOI: https://doi.org/10.1136/thoraxjnl-2021-218088

Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium in patients with COPD: the tri-d randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2021;16:79-89. DOI: https://doi.org/10.2147/COPD.S291030

PrescQIPP. Bulletin 295 - inhaler carbon footprint. [consultado 2024 mai 22]. Disponível em: https://www.prescqipp.info/our-resources/bulletins/ bulletin-295-inhaler-carbon-footprint/.

Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: an observational comparative study. Chron Respir Dis. 2017;14:309-20. DOI: https://doi.org/10.1177/1479972316687209

Campos L, Barreto JV, Bassetti S, Bivol M, Burbridge A, Castellino P, et al. Physicians’ responsibility toward environmental degradation and climate change: a position paper of the European Federation of Internal Medicine. Eur J Intern Med. 2022;104:55-8. 30. Campos L, Chimeno-Viñas MM, Carretero-Gómez J, Santos L, Cabrera- Rayo A, Valdez PR, et al. Recommendations of the Spanish-Portuguese internal medicine services in the fight against climate change and environmental degradation. Rev Clín Esp. 2024;224:162-6. DOI: https://doi.org/10.1016/j.rceng.2024.02.005

Downloads

Published

2024-10-07

How to Cite

1.
Campos L, Rosa P, Carreiro Martins P, Xavier B, Leuschner P, M. Marques MI, Albino J, Robalo Cordeiro C. Correction to the Article “Recommendations for Reducing the Environmental Impact of Inhalers in Portugal: Consensus Document”, Published on Acta Med Port 2024 Sep;37(9):654-661. Acta Med Port [Internet]. 2024 Oct. 7 [cited 2024 Nov. 5];37(11):817-8. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/22395

Issue

Vol. 37 No. 11 (2024): November

Section

Errata

License

Copyright (c) 2024 Acta Médica Portuguesa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC